StockNews.AI
SLN
StockNews.AI
187 days

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

1. Silence Therapeutics will announce Q4 and full year 2024 results on February 27, 2025. 2. A conference call at 8:00 a.m. ET will discuss financial results and updates. 3. The company develops siRNA therapies targeting significant unmet medical needs. 4. Silence focuses on diseases in cardiovascular, hematology, and rare disorders. 5. The earnings call could influence investor sentiment towards SLN's financial health.

Earnings
+18.49%Current Return
VS
+1.08%S&P 500
$4.1102/13 08:42 AM EDTEvent Start
$4.8702/14 03:22 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Earnings announcements typically have mixed effects. Previous calls for SLN showed volatility but not a strong trend.

How important is it?

The upcoming earnings report is crucial for assessing SLN's financial stability and growth prospects. However, results are uncertain until announced.

Why Short Term?

A scheduled earnings report can quickly influence stock movements. Past earnings announcements have resulted in immediate price adjustments.

Related Companies

SLN
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025. Management will host a conference call at 8:00 a.m. ET / 1:00 p.m. GMT that day to discuss the Company’s financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the Company’s website. Details of the webcast and conference call: Webcast link: https://edge.media-server.com/mmc/p/73gzxc8m Conference call registration link: https://register.vevent.com/register/BIbb8ec3d3557e47e3a4db7b8c03339124 About Silence Therapeutics Silence Therapeutics is a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https://www.silence-therapeutics.com/.

Related News